xCures and Aetion expand partnership, broadening access to valuable real-world evidence for enhanced oncology research

xCures and Aetion, two leading companies in the oncology research domain, have strengthened their partnership to provide access to five comprehensive oncology datasets, significantly expanding the pool of real-world evidence (RWE) available for advancing cancer research. This collaboration marks a significant milestone in advancing personalized cancer care, empowering researchers to develop more effective treatments and improve patient outcomes.

In the landscape of oncology research, having access to diverse, comprehensive, and fully longitudinal datasets is invaluable. xCures, operating an AI-assisted platform, plays a pivotal role by automatically retrieving and aggregating medical records from all US care sites. This sophisticated platform enables rapid data extraction and structuring within 15 minutes, providing researchers with a comprehensive view of a patient’s health journey, from genomics to social determinants of health. These datasets offer an intricate understanding of patient journeys across the US, enabling researchers to glean clinically relevant insights crucial for shaping the future of cancer care.

The current challenge in oncology outcomes research lies in the fragmentation of patient data across various healthcare providers and care sites, which results in substantial gaps in understanding patient outcomes and treatment efficacies. xCures addresses this challenge by consolidating and structuring clinical, genomic and imaging data directly from electronic medical records, healthcare providers, and other care sites. This comprehensive, patient-centric approach equips researchers and clinicians with up-to-date and thorough information, facilitating more informed and timely treatment decisions.

As part of this expanded partnership, Aetion, a leader in RWE and analytics, will incorporate xCures’ breast cancer, glioma, melanoma, colorectal cancer, and ovarian/uterine cancer datasets into their Accelerated Access Oncology Program. These datasets will contribute to Aetion’s collaboration with the Food and Drug Administration, enhancing the breadth and depth of RWE available for analysis.

Mika Newton, CEO of xCures, expressed enthusiasm about the partnership, stating, “It is a testament to the power of collaborative efforts in advancing oncology research. By bringing our real-time, regulatory-grade, clinical data (RRC) to a broader audience, we are not just sharing information – we are empowering a shift towards more effective, patient-centric cancer treatments.”

Wendy Turenne, Senior Vice President, Real World Data & Operations at Aetion, highlighted the unique value of xCures’ datasets, stating, “We are delighted to partner with xCures, as their datasets provide a unique lens into the patient’s experience. In combination with Aetion Substantiate, these data can be analyzed in novel ways and shorten the time to generate and deliver critical insights that will help shape the future of cancer treatment.”

This collaboration signifies a joint commitment to advancing oncology research, offering researchers, providers, and partners a robust platform to extract meaningful insights and drive innovation in cancer care.

---

You may also be interested in:

SURF screening tool to determine suitability of using real-world evidence